Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Allergan’s depression drug fails in Phase III trials

Rapastinel is being developed as a NMDA receptor modulator to treat depression. Credit: Counselling via Pixabay.

  • Allergan’s depression drug rapastinel fails in Phase III trials

Go Top